Across TCGA pan-cancer cohorts, MZT1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MZT1 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MZT1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MZT1 expression acts as an unfavorable survival marker.

HNSC, BLCA, and KIRC are the cancer types where MZT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.075	0.768	<.001	48	view →
BLCA	OS	Median	All	0.069	0.688	<.001	27	view →
KIRC	OS	Median	All	0.122	0.629	.019	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MZT1 tumor-vs-normal RNA expression · all MZT1 data types